Vaxart Inc

+0.08 (+3.59%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)275.20M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.05 Million
Adjusted EPS-$0.24
See more estimates
10-Day MA$2.33
50-Day MA$3.35
200-Day MA$4.30
See more pivots

Vaxart Inc Stock, NASDAQ:VXRT

170 Harbor Way, Suite 300, South San Francisco, California 94080
United States of America
Phone: +1.650.550.3500
Number of Employees: 125


Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.